February 2026 in “South Asian Research Journal of Biology and Applied Biosciences” In this study, patients with alopecia areata had significantly higher levels of luteinizing hormone and follicle-stimulating hormone compared to healthy controls, suggesting a link between hormone levels and the disease.
14 citations
,
November 2014 in “European journal of medicinal chemistry” This study identified 30 new compounds with significant androgen receptor binding affinity through a combination of virtual screening and in vitro testing.
January 2024 in “Journal of Applied Pharmaceutical Science” This study identified procyanidin B2 and leucopelargonidin from Saraca asoca as potential inhibitors in PCOS by showing high binding energy scores against key enzymes involved in estrogen and testosterone biosynthesis.
January 2020 in “International Journal of Medical Research and Health Sciences” This study discusses the prevalence of PCOS risk factors among female students at Northern Border University but reports no new clinical results, emphasizing the need for awareness and further investigations.
July 2025 in “Future Journal of Pharmaceuticals and Health Sciences” This study developed a polyherbal chocolate formulation aimed at managing PCOS and hormonal balance, finding that formulation F2 showed excellent organoleptic properties and stability, with future in vivo studies being suggested.
September 2024 in “Reproduction and Fertility” This review highlights the limited effectiveness of current unlicensed treatments for male subfertility, like hormonal therapy and antioxidants, and emphasizes new drug discovery methods such as high-throughput screening and drug repurposing to improve treatment development for male subfertility.
June 2024 in “Biological and Clinical Sciences Research Journal” In this study, researchers found that women with PCOS and thyroid dysfunction had significantly altered T3 and T4 hormone levels and more frequent symptoms like weight gain and irregular menstrual cycles, suggesting the importance of thyroid screenings for personalized treatment strategies.
28 citations
,
October 2018 in “Clinical Obstetrics and Gynecology” This study suggests that gender-affirming testosterone therapy in transgender men is generally safe and effective with adequate screening and monitoring, although high-quality long-term studies are lacking.
3 citations
,
September 2024 in “Journal of Pre-Clinical and Clinical Research” This study reviews the current understanding of psychiatric disorders in women with PCOS, finding links to the gut-brain axis, neurotransmitter and neuroendocrine dysfunction, and suggests the need for routine mental health screening in these patients.
This study found a significant association between increased waist circumference and body mass index and female pattern hair loss in premenopausal women, suggesting the importance of screening for metabolic syndrome in these patients.
September 2022 in “Translational Andrology and Urology” This study found that in young men with post-finasteride syndrome, there are potential genetic risk factors associated with psychological and sexual dysfunctions, suggesting genetic screening may be beneficial before prescribing finasteride.
16 citations
,
January 2019 in “LGBT health” Transgender women can still get testicular cancer, so proper screening is important.
November 2024 in “Revista de Investigación y Educación en Ciencias de la Salud (RIECS)” In this case study, a 7-year-old girl was diagnosed with Isolated Premature Pubarche after presenting with pubic hair growth and normal hormonal and bone age assessments.
46 citations
,
January 2007 in “The European Journal of Contraception & Reproductive Health Care” This review discusses the increased risk of venous thromboembolism associated with combined hormonal contraceptives, particularly noting higher risks with certain progestins like desogestrel, gestodene, and cyproterone acetate, but reports no new clinical findings.
1 citations
,
November 2007 in “Humana Press eBooks” This article reviews the differential diagnosis and management approaches for androgen excess disorders, highlighting the predominance of polycystic ovary syndrome as the underlying cause and reports no new clinical findings.
September 2024 in “Research Square (Research Square)” This study observed that 65.6% of acne patients also had PCOS, with these individuals showing more severe acne, higher testosterone levels, and greater prevalence of hirsutism and androgenic alopecia compared to those with isolated acne.
This study found that in men with androgenetic alopecia, elevated triglycerides were the only factor consistently associated with the condition, suggesting a potential link between AGA and lipid metabolism, although other hormonal, metabolic, and sleep factors were not significantly different after propensity score matching.
3 citations
,
January 2020 in “Indian Dermatology Online Journal” In this study, significant correlations were observed between acanthosis nigricans and factors like free testosterone, DHEAS, fasting blood sugar, and BMI, as well as between hirsutism and elevated DHEAS, free testosterone, and BMI among patients with polycystic ovarian disease.
47 citations
,
February 2019 in “Journal of The American Academy of Dermatology” This article reviews the unique health issues and preventive care recommendations for LGBT individuals, emphasizing dermatologic considerations and the importance of culturally competent care, but reports no new clinical findings.
1 citations
,
March 2011 in “Informa Healthcare eBooks” Hormonal therapy is effective for treating acne in adult women, especially with signs of high androgen levels.
373 citations
,
September 2009 in “Obstetrics & Gynecology” This review examines the best available evidence for diagnosing and managing PCOS but reports no new clinical results.
17 citations
,
November 2000 in “Journal of the American Pharmaceutical Association” This review discusses the perimenopause, its symptoms, and management options, emphasizing the role of pharmacists in educating and advising women on treatment strategies and preventive health measures, but it reports no new results.
16 citations
,
January 2019 in “Kansas journal of medicine” This source outlines what it takes to be a competent provider for transgender individuals, focusing on their health needs, disparities, and coverage, and examines medical biases and hormone treatment guidelines, alongside treatment options for different age groups, concluding with evolving trends in medical education.
9 citations
,
November 2016 in “Journal of medical science and clinical research” In this study, the prevalence of clinical polycystic ovary syndrome among high school girls in Sambalpur, Odisha, was found to be 12%.
9 citations
,
November 2008 in “Journal of Womens Health” This study found that recruiting healthy naturally menopausal women for a DHEA therapy trial was challenged by concerns about hormonal treatments and time constraints, impacting study feasibility.
3 citations
,
January 2019 in “Cureus” This review discusses confluent and reticulated papillomatosis in polycystic ovarian syndrome patients, noting successful treatment with azithromycin in one case, and suggests potential association with acanthosis nigricans; it reports no new results.
2 citations
,
January 2012 in “Journal für Kardiologie (Krause & Pachernegg GmbH)” This review discusses therapeutic principles for managing hirsutism and androgenetic alopecia during the menopausal transition and peri-/postmenopause but reports no new clinical results.
1 citations
,
June 2021 in “Journal of gynecology and womens health” This study found that the prevalence of polycystic ovarian syndrome among women of reproductive age in urban and rural areas of Hyderabad, Telangana, is between 6.5% and 6.8%.
1 citations
,
May 2016 in “The Nurse Practitioner” This article reviews current guidelines for diagnosing, treating, and providing holistic care for women with polycystic ovary syndrome, without presenting new clinical findings.
June 2026 in “British Journal of Dermatology” This study found that individuals with frontal fibrosing alopecia have increased odds of thyroid disease, lupus erythematous, vitiligo, and heart disease, supporting the consideration of FFA as a systemic disorder.